Prostaglandin H2 Causes Calcium Mobilization in Intact Human Platelets

  • L. D. Brace
  • G. C. Le Breton
  • D. L. Venton
Part of the GWUMC Department of Biochemistry Annual Spring Symposia book series (GWUN)


It was originally suggested that thromboxane A2 (TxA2) production is a prerequisite for platelet activation induced by arachidonic acid (AA) addition. More recently, however, evidence has accumulated that suggests that, under the appropriate conditions, prostaglandin H2 (PGH2) can also play a role in the platelet activation process. In this regard, Needleman et al. (1976) have shown that when AA was added to washed platelets incubated with the thromboxane synthase inhibitor im-idazole (Needleman et al., 1976, 1977a,b; Moncada et al., 1976, 1977), thromboxane synthesis was blocked, but platelet aggregation was not inhibited (Needleman et al., 1977b). Based on these findings, they proposed that PGH2 is itself active in causing platelet aggregation.


Calcium Mobilization Heptanoic Acid Thromboxane Synthetase Thromboxane Synthesis TxA2 Production 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Born, G.V.R., 1962, Aggregation of blood platelets by adenosine diphosphate and its reversal, Nature 194:927–929.PubMedCrossRefGoogle Scholar
  2. Brace, L.D., Venton, D.L., and Le Breton, G.C, 1982, Thromboxane A2/prostaglandin H2 mobilizes calcium in human blood platelets, Circulation [Suppl.] 64:1198.Google Scholar
  3. Caswell, A. H., and Hutchison, J. D., 1971, Visualization of membrane bound cations by a fluorescent technique, Biochem. Biophys. Res. Commun. 42(1):43–49.PubMedCrossRefGoogle Scholar
  4. Fain, J. N., Pointer, R. H., and Ward, W. F., 1972, Effects of adenosine nucleosides on adenylate cyclase, phosphodiesterase, cyclic adenosine monophosphate accumulation and lipolysis in fat cells, J. Biol. Chem. 247(21):6866–6872.PubMedGoogle Scholar
  5. Feinman, R. D., Lubowsky, J., Charo, I., and Zabinski, M. P., 1977, The lumiaggregometer: A new instrument for simultaneous measurement of secretion and aggregation, J. Lab. Clin. Med. 90(1):125–129.PubMedGoogle Scholar
  6. Feinstein, M. B., 1980, Release of intracellular membrane-bound calcium precedes the onset of stimulus-induced exocytosis in platelets, Biochem. Biophys. Res. Commun. 93(2):593–600.PubMedCrossRefGoogle Scholar
  7. Feinstein, M. B., Egan, J. J., Sha’afi, R. I., and White, J., 1983, The cytoplasmic concentration of free calcium in platelets is controlled by stimulators of cyclic AMP production (PGD2, PGE1, forskolin), Biochem. Biophys. Res. Commun. 113(2):598–604.PubMedCrossRefGoogle Scholar
  8. Feuerstein, N., and Ramwell, P.W., 1981, OKY-1581, a potential selective thromboxane synthetase inhibitor, Eur. J. Pharmacol. 69:533–534.PubMedCrossRefGoogle Scholar
  9. Fitzpatrick, F.A., and Gorman, R.R., 1978, A comparison of imidazole and 9,ll-azoprosta-5,13-dienoic acid: Two selective thromboxane synthetase inhibitors, Biochim. Biophys. Acta 539:162–172.PubMedCrossRefGoogle Scholar
  10. Fitzpatrick, F. A., Gorman, R. R., McGuire, J. C, Kelly, R. C, Wynalda, M. A., and Sun, F. F., 1977, A radioimmunoassay for thromboxane B2, Anal. Biochem. 82(1): 1–7.PubMedCrossRefGoogle Scholar
  11. Gorman, R., Sun, F., Peterson, D., Sun, F., Miller, O., and Fitzpatrick, F., 1977, Inhibition of human platelet thromboxane synthetase by 9,1 l-azoprosta-5,13-dienoic acid, Proc. Natl. Acad. Sci. U.S.A. 74(9):4007–4011.PubMedCrossRefGoogle Scholar
  12. Grimm, L.J., Knapp, D.R., Senator, D., and Halushka, P.V., 1981, Inhibition of platelet thromboxane synthesis by 7-(l-irnidazolyl)heptanoic acid: Dissociation from inhibition of aggregation, Thromb. Res. 24:307–317.PubMedCrossRefGoogle Scholar
  13. Hung, S.C, Ghali, N.I., Venton, D.L., and Le Breton, G.C, 1983, Specific binding of the thromboxane antagonist 13-azaprostanoic acid to human platelet membranes, Biochim. Biophys. Acta 728:171–178.PubMedCrossRefGoogle Scholar
  14. Kawahara, Y., Yamanashi. J. Furuta, Y., Kaibuchi, K., Takai, Y., and Fukuzaki, H., 1983, Elevation of cytoplasmic free calcium concentration by stable thromboxane A2 analogue in human platelets, Biochem. Biophys. Res. Commun. 117(3):663–669.PubMedCrossRefGoogle Scholar
  15. Kayama, N., Sakaguchi, K., Kaneko, S., Kutoba, T., Fukuzawa, T., Kawamura, S., Yoshimoto, T., and Yamamoto, S., 1981, Inhibition of platelet aggregation by 1-alkylimidazole derivatives, thromboxane A synthetase inhibitors, Prostaglandins 21(4):543–554.PubMedCrossRefGoogle Scholar
  16. Le Breton, G. C, Dinerstein, R. J., Roth, L. J., and Feinberg, H., 1976, Direct evidence for intracellular divalent cation distribution associated with platelet shape change, Biochem. Biophys. Res. Commun. 71(1):362–370.PubMedCrossRefGoogle Scholar
  17. Le Breton, G.C, Venton, D.L., Enke, S.E., and Halushka, P.V., 1979, 13-Azaprostanoic acid: A specific antagonist of the human blood platelet thromboxane/endoperoxide receptor, Proc. Natl. Acad. Sci. U.S.A. 76:4097–410PubMedCrossRefGoogle Scholar
  18. Miyamoto, T., Tanaiguchi, K., Tanouchi, T., and Hirata, F., 1980, Selective inhibitor of thromboxane synthetase: Pyridine and its derivatives, Adv. Prostaglandin Thromboxane Res. 6:443–445.PubMedGoogle Scholar
  19. Moncada, S., Needleman, P., Bunting, S., and Vane, J. R., 1976, Prostaglandin endoperoxide and thromboxane generating systems and their selective inhibition, Prostaglandins 12(3):323–335.PubMedCrossRefGoogle Scholar
  20. Moncada, S., Bunting, S., Mullane, K., Thorogood, P., Vane, J. R., Raz, A., and Needleman, P., 1977, Imidazole: A selective potent antagonist of thromboxane synthetase, Prostaglandins 13(4):611–618.PubMedCrossRefGoogle Scholar
  21. Needleman, P., Minkes, M., and Raz, A., 1976, Thromboxane: Selective biosynthesis and distinct biological properties, Science 193:163–165.PubMedCrossRefGoogle Scholar
  22. Needleman, P., Bryan, B., Wyche, A., Bronson, S. D., Eakins, K., Ferrendelli, J. A., and Minkes, M., 1977a, Thromboxane synthetase inhibitors as pharmacological tools: Differential biochemical and biological effects on platelet suspensions, Prostaglandins 14(5):897–907.PubMedCrossRefGoogle Scholar
  23. Needleman, P., Raz, A., Ferrendelli, J. A., and Minkes, M., 1977b, Application of imidazole as a selective inhibitor of thromboxane synthetase in human platelets, Proc. Natl. Acad. Sci. U.S.A. 74(4):1716–1720.PubMedCrossRefGoogle Scholar
  24. Owen, N. E. and Le Breton, G. C, 1981, Ca2+ mobilization in blood platelets as visualized by chlortetracycline fluorescence, Am. J. Physiol. 241:H613–H619.PubMedGoogle Scholar
  25. Randall, M.J., Parry, M.J., Hawkeswood, E., Cross, P.E., and Dickenson, R.P., 1981, UK-37,248, a novel, selective thromboxane synthetase inhibitor with platelet antiaggregatory and anti-thrombotic activity, Thromb. Res. 23:145–162.PubMedCrossRefGoogle Scholar
  26. Rybicki, J.P., and Le Breton, G.C, 1983, Prostaglandin H2 directly lowers human platelet cAMP levels, Thromb. Res. 30:407–414.PubMedCrossRefGoogle Scholar
  27. Rybicki, J.P., Venton, D.L., and Le Breton, G.C, 1983, The thromboxane antagonist, 13-azaprostanoic acid, inhibits arachidonic acid-induced Ca2+ release from isolated platelet membrane vesicles, Biochim. Biophys. Acta 751:66–73.PubMedCrossRefGoogle Scholar
  28. Smith, J.B., 1982, Effect of thromboxane synthetase inhibitors on platelet function: Enhancement by inhibition of phosphodiesterase, Thromb. Res. 28:477–485.PubMedCrossRefGoogle Scholar
  29. Smith, J.B., Ingerman, C.M., and Silver, M.J., 1974, Prostaglandin D2 inhibits the aggregation of human platelets, Thromb. Res. 5:291–299.PubMedCrossRefGoogle Scholar
  30. Smith, J.B., Ingerman, C.M., and Silver, M.J., 1976, Formation of prostaglandin D2 during en-doperoxide-induced platelet aggregation, Thromb. Res. 9:413–418.PubMedCrossRefGoogle Scholar
  31. Tai, H., Lee, N., and Tai, C.L., 1980, Inhibition of thromboxane synthesis and platelet aggregation by pyridine and its derivatives, Adv. Prostaglandin Thromboxane Res. 6:447–452.PubMedGoogle Scholar
  32. Venton, D. L., Enke, S. E., and Le Breton, G. C, 1979, Azaprostanoic acid derivatives. Inhibitors of arachidonic acid induced platelet aggregation, J. Med. Chem. 22(7):824–830.PubMedCrossRefGoogle Scholar
  33. White, J. G., 1972, Interaction of membrane systems in blood platelets, Am. J. Pathol. 66(2):295–312.PubMedGoogle Scholar
  34. Yoshimoto, T., Yamamoto, S., and Hayaishi, O., 1978, Selective Inhibition of prostaglandin endo-peroxide thromboxane isomerase by 1-carboxylalkylimidazoles, Prostaglandins 16(4):529–540.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1985

Authors and Affiliations

  • L. D. Brace
    • 1
  • G. C. Le Breton
    • 1
  • D. L. Venton
    • 2
  1. 1.Department of PharmacologyThe University of Illinois at Chicago, Health Sciences CenterChicagoUSA
  2. 2.Department of Medicinal ChemistryThe University of Illinois at Chicago, Health Sciences CenterChicagoUSA

Personalised recommendations